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Abstract
The C-type lectin-like receptor CD161 is a well-established marker for human IL17-producing T cells, which have been
implicated to contribute to the development of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation
(allo-SCT). In this study, we analyzed CD161+ T cell recovery, their functional properties and association with GVHD
occurrence in allo-SCT recipients. While CD161+CD4+ T cells steadily recovered, CD161hiCD8+ T cell numbers declined during
tapering of Cyclosporine A (CsA), which can be explained by their initial growth advantage over CD161neg/lowCD8+ T cells
due to ABCB1-mediated CsA efflux. Interestingly, occurrence of acute and chronic GVHD was significantly correlated with
decreased levels of circulating CD161+CD4+ as well as CD161hiCD8+ T cells. In addition, these subsets from transplanted
patients secreted high levels of IFNc and IL17. Moreover, we found that CCR6 co-expression by CD161+ T cells mediated
specific migration towards CCL20, which was expressed in GVHD biopsies. Finally, we demonstrated that CCR6+ T cells
indeed were present in these CCL20+ GVHD-affected tissues. In conclusion, we showed that functional CD161+CCR6+ co-
expressing T cells disappear from the circulation and home to GVHD-affected tissue sites. These findings support the
hypothesis that CCR6+CD161-expressing T cells may be involved in the immune pathology of GVHD following their CCL20-
dependent recruitment into affected tissues.
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Introduction
Graft-versus-host disease (GVHD) is still one of the major causes
of morbidity and mortality after allogeneic stem cell transplanta-
tion (allo-SCT) [1]. The pathophysiology of GVHD is a multistep
process involving tissue damage and pro-inflammatory cytokine
cascades induced by the pre-transplant conditioning regimen
[1,2]. This results in an excessive inflammatory environment in
which donor-derived CD4+ and CD8+ T cells become potently
activated. In addition, T cell trafficking towards inflamed GVHD-
prone organs including skin, lung, gastrointestinal tract, and liver
is increased. Further tissue destruction in these organs occurs in
the case of presentation of ubiquitous or epithelial expressed allo-
antigens to infiltrating allo-reactive cytotoxic T cells. Moreover,
macrophages, and other effector T cells subsets are recruited,
resulting in further enhancement of GVHD [1,3–5]. In particular,
Th1-type CD4+ T cells and Tc1-type CD8+ T cells play an
important role in GVHD pathophysiology [6,7], but other T cell
subsets with specific phenotype and functional characteristics
might play a pivotal role as well.
The contribution of pro-inflammatory Th17 cells in various
autoimmune disorders has raised the question of the role of IL17-
producing T cells in GVHD. Although some mouse studies
showed that these T cells are involved in the onset and persistence
of GVHD [8–11], others claim a protective role of Th17 cells [12].
Furthermore, human studies performed on Th17 cells also show
conflicting results [13–16]. An increase in circulating Th17 cells,
as well as an imbalance between Th17 and regulatory T cells, has
been correlated with occurrence of GVHD [13–15]. However,
Broady et al. found an expansion of Th1 rather than Th17 cells in
GVHD-affected skin [13]. Though, Bossard et al. recently showed
that the absolute number of Th17 cells using the markers CD161,
RORct, and CC chemokine receptor (CCR)6 were significantly
higher in intestinal mucosa of patient with acute GVHD [16].
Regarding the proposed plasticity of Th17 responses [17], CD161
and CCR6 may be more reliable surface markers to study the
involvement of Th17 and Tc17 cells in GVHD.
Interestingly, it has been shown that CD161 is a distinguishing
surface marker for both CD4+ and CD8+ T cell subsets producing
IL17 and/or IFNc [18,19]. CD161, also known as killer cell lectin-
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like receptor superfamily B member 1 (KLRB1) or natural killer
receptor protein 1a (NKRP1a), is a type II membrane glycoprotein
with characteristics of the C-type lectin superfamily [20]. The
function of CD161 on T cells has not been clearly defined yet, but
a role in T cell co-stimulation has been indicated [21,22].
Furthermore, CD161 has been implicated to play a role in trans-
endothelial migration [23,24]. CD161 is moderately expressed on
CD4+ T cells, but within the CD8+ T cells population a distinct
subset clearly expresses high levels of CD161 [25–32]. The
comparable phenotype between Th17 cells and CD161hiCD8+ T
cells, including explicit IL17-production and their expression of
RORct [25,27,30], suggests that these cells are the equivalent of
Th17 cells within the CD8+ T cell population, namely Tc17 cells.
Distinctively, CD161-expressing T cells display high levels of the
chemokine receptor CCR6, for which we recently showed that a
single nucleotide polymorphism in this gene correlates with
occurrence of chronic GVHD [33]. CCR6 has only one ligand,
CCL20, which is constitutively expressed in organs such as the
liver, colon, small intestine, lung, and skin [34]. Furthermore,
damage of the epidermal permeability barrier, as well as
stimulation with IL1ß, results in up-regulation of CCL20
expression [35,36]. This suggests that CD161-expressing T cells
have the capability to migrate to the target organs involved in
GVHD.
In this study, we investigated the repopulation kinetics,
functional properties, and associations with GVHD of CD161-
expressing CD4+ and CD8+ T cells in patients who received allo-
SCT for a haematological malignancy. We observed that
decreased levels of circulating CD161-expressing T cells, with
the specific migratory capacity towards CCL20 expressed in
GVHD tissues, and the potential to secrete IL17 and IFNc,
correlate with the occurrence of GVHD.
Materials and Methods
Patients and Healthy Controls
Patients treated between 1993 and 2008 with allo-SCT for a
haematological malignancy in the Radboud University Nijmegen
Medical Centre were included in this study (Table 1). All patients
received a HLA-matched sibling allo-SCT which, irrespective of
donor source or conditioning regimen, were partially depleted of T
cells. Until November 2001 counterflow centrifugation elutriation
was used [37], and from that moment onwards T cell depletion
was performed with immunomagnetic CD34-enrichment or
CD3/CD19 depletion (Miltenyi Biotec) [38]. CD3+ T cells were
added back in the graft with a median 6 SD of 0.4360.516106
cells/kg bodyweight. GVHD prophylaxis consisted of Cyclospor-
ine A (CsA) in almost all patients, and was dosed 1.5 mg/kg
bidaily intravenously for the first two weeks, and thereafter 1 mg/
kg bidaily intravenously or 2.5–3 mg/kg bidaily orally. Tapering
of CsA was started in the absence of GVHD after two months and
stopped at three months. The occurrence of acute GVHD was
graded according to the criteria by Przepiorka et al. [39]. Chronic
GVHD was classified according to the revised Seattle criteria of
Lee et al. [40]. PBMCs were isolated using Ficoll-Hypaque
gradient from PB samples that were collected at several time
points after allo-SCT. Absolute cell levels were calculated using the
lymphocyte count from the PB sample and the percentages of the
different T cells populations measured in the PBMCs. PBMCs of
healthy controls were isolated from buffy coats supplied by the
Sanquin Blood Supply Foundation. Patients and healthy donors
had given their informed consent which was approved by the
RUNMC Institutional Review Board.
Flow Cytometry
Flow cytometry was performed using the following directly
conjugated antibodies: CD3 (UCHT1, Beckman Coulter, Biole-
gend), CD4 (13B8.2, Beckman Coulter; OKT4, Biolegend), CD8
(3B5, Invitrogen), CD45RA (H100, Biolegend), CD161 (191B8,
Miltenyi Biotech), CCR6 (53103, R&D Systems), CCR7 (150503,
R&D Systems; G043H7, Biolegend). Expression of CD161 and
additional markers was determined by staining for 30 minutes at
4uC. Cells were washed with phosphate-buffered saline (PBS)/
0.5% BSA (Sigma). To determine the Rhodamine 123 (Rh123,
Sigma) efflux, cells were labelled with 10 mg/ml Rh123 in IMDM
containing 1% BSA for 30 minutes at 4uC. Then, cells were
incubated for 30 minutes in the cell incubator at 37uC, followed by
a standard staining procedure. Cells were measured on the Cyan-
ADP 9 color analyzer (Beckman Coulter). Analysis was performed
using Summit software.
Quantative RT-PCR
Quantitative RT-PCR for expression of the ABCB1 transporter
was performed on T cell subsets. From both CD4+ and CD8+ T
cells, CD161-subsets were sorted on a FACS ALTRA (Beckman
Coulter). Total RNA was extracted using the Quick-RNA
miniPrep isolation kit (Zymo Research) in accordance with the
manufacturer’s instructions. Subsequently, cDNA was generated
using standard methods [41]. ABCB1 expression was determined
using the following primers and probe: ABCB1-forward, 59-
ACTGAGCCTGGAGGTGAAGAAG-39; ABCB1-reverse, 59-
TTTGCCATCAAGCAGCACTT-39; ABCB1-probe, 59-FAM-
Table 1. Patient characteristics.
Characteristic n= 76
Age at transplantation, years (median, range) 47 (19–63)
Sex, no. males (%) 42 (55%)
Underlying disease, no. (%)
- ALL/AML/MDS 53 (70%)
- CML 11 (14%)
- NHL/CLL 12 (16%)
Conditioning regimen, no. (%)
- Cy-Bus 4 (5,5%)
- Cy-TBI 10 (13%)
- Ida-Cy-Bus 7 (9%)
- Ida-Cy-TBI 55 (72,5%)
Graft source
- Bone marrow 32 (42%)
- Peripheral Blood 44 (58%)
Acute GVHD, no. (%)
- Grade 1–4 40 (53%)
- Grade 3–4 9 (12%)
Chronic GVHD, no. (%)
- Limited 17 (22%)
- Extensive 14 (18%)
Abbreviations: ALL, acute lymphatic leukemia; AML, acute myeloid leukemia;
MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; NHL, non-
Hodgkin lymphoma; CLL, chronic lymphatic leukemia; Cy, cyclophosphamide;
Bus, busulphan; TBI, total body irradiation; Ida, idarubicin; GVHD, graft-
versus-host disease.
doi:10.1371/journal.pone.0050896.t001
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TCCTGGAGCGGTTCTACGACCCCTT-39. Reactions were
run on an ABI 7900-HT Real-time PCR System and analyzed
with Sequence Detection Systems 2.3 software (Applied Biosys-
tems). Expression is shown in DDCt values and was quantified
relative to CD1612CD4+ T cells, which was set at 1 DDCt value.
DDCt was calculated as follows: 2‘(-DCtsample2 DCtCD1612CD4+ T
cells), in which DCt was normalized for the porphobilinogen
deaminase (PBGD) housekeeping gene by calculating
DCt=CtABCB1 2 CtPBGD per sample.
T Cell Proliferation Assay
To compare the effect of immunosuppressive drugs on
proliferation of CD161hi versus CD161neg/lowCD8+ T cells,
PBMCs from healthy controls were labelled with 5 mM carboxy-
fluorescein diacetate succinimidyl (CFSE, Molecular Probes
Europe) for 15 minutes at 37uC in IMDM. Cells were stimulated
in a mixed lymphocyte reaction (MLR) using irradiated allo-
PBMCs in IMDM (Invitrogen)/10% human serum (HS, PAA
Laboratories), 200 U/ml IL2 (Chiron), 5 ng/ml IL7 (Immuno-
tools), and 5 ng/ml IL15 (Immunotools). CsA (BioVision) was
added at the start of the MLR culture. CFSE levels of CD161hi
and CD161neg/lowCD8+ T cells were measured by flow cytometry
after seven days.
Intracellular Cytokine Staining
To determine the cytokine production by the different T cell
subsets, intracellular cytokine staining was performed. PBMCs
were stimulated with PMA and ionomycin for 4 hours with
Brefeldin A (all BD) present for the last 3 hours. Cells were stained
for CD3, CD4, CD8, and CD161 as described. Then cells were
fixated, permeabilized (eBioscience), and stained for IL17
(eBioscience) and IFNc (BD). Non-stimulated cells and IgG1
(Dako) stainings were used as controls.
Immunohistochemistry
Enzymatic immunohistochemical staining for CCL20 was
performed as described previously [42] on 4 mM formalin fixed
paraffin embedded tissue sections prepared from skin and gut
biopsies obtained from patients diagnosed with either acute or
chronic GVHD. Briefly, after baking for 1 hour at 66uC, slides
were subsequently deparaffinised in xylol and rehydrated in a
series of ethanol. Endogenous peroxidase was blocked using
methanol/0.3% H202 for 20 minutes. The sections were then
subjected to heat mediated antigen retrieval in a microwave using
10 mM citrate buffer (pH 6.0). Anti-CCL20 (R&D Systems) was
diluted in PBS/1% BSA and the sections were incubated
overnight at RT in a humidity chamber. Anti-CCL20 was
detected enzymatically using Powervision (Dako) followed by
colour development with 3.3-diaminobenzidine. After counter-
staining with haematoxylin, the sections were mounted in Pertex.
Triple immunofluoresent staining was performed in parallel on
tissue sections that were subjected to deparaffinization and antigen
retrieval as described above. Note that endogenous peroxidise
blocking was not performed. Primary antibodies specific for CD3
(DAKO), CD4 (R&D Systems), and CCR6 (R&D Systems), were
diluted in PBS/1% BSA and the sections were incubated
overnight at RT in a humidity chamber. Bound antibodies were
detected with appropriated diluted secondary antibodies (donkey
anti-rabbit IgG Alexa-546, donkey anti-mouse IgG Alexa-488 and
donkey anti-goat Alexa-647, all from Invitrogen). After washing in
PBS, the sections were mounted in moviol.
Migration Assay
Migration towards CCL20 was measured in 96 or 24 well plates
containing transwell inserts with 5 mm pores (Costar). IMDM/
10% HS with CCL20 (Immunotools) was added to the lower
compartment. CD3+, CD4+ or CD8+ T cells were selected using
the standard MACS procedure (Miltenyi Biotech) and 0.75 or
2.56106 cells were loaded into the inserts. After 2 hours in a 37uC
incubator, cells in the lower compartment were harvested and
labelled for CD3, CD4 or CD8, and CD161. Migration was
determined by flow cytometry by acquiring events for a fixed time
period and presented as the relative migration compared to input.
Statistical Analysis
Statistical analysis for experimental data was performed using
GraphPad Prism 4. Statistical significance of difference was
analyzed using an one-tailed student t-test, parametric, non-
parametric, one-way or two-way analysis of variance (ANOVA),
followed by the appropriate post-hoc test, all as indicated in the
figure legends. Correlation analysis was performed by calculating
the Spearman correlation coefficient.
Associations of CD161+CD4+ and CD161hiCD8+ T cells with
the occurrence of acute or chronic GVHD after allo-SCT were
tested using univariate logistic regression analysis. To this end the
percentages and absolute cell counts of CD161hiCD8+ levels, as
well as the absolute levels of CD161+CD4+ T cells were
logarithmically transformed because of their positive skewing. To
correct for possible confounders, we used multivariate logistic
regression analyses. Regression analyses were performed using
SAS 8.2 software. For all analyses P,0.05 were considered to be
significant.
Results
Determining the Normal Distribution of CD161-
expressing T Cells in Healthy Controls
In order to evaluate the repopulation kinetics of CD161+CD4+
and CD161hiCD8+ T cells in allo-SCT recipients, we first
determined their frequency and absolute numbers in peripheral
blood (PB) of healthy controls. Within the CD4+ T cell population,
a clear CD161+ subset could be identified, with an average 6 SD
of 17.765.8% and 174.1647.86106 CD161+CD4+ T cells/L
(Figure S1A–B, n=16). As expression levels of CD161 were higher
on CD8+ T cells, CD8+ T cells were divided in CD161neg/low and
CD161hi cells (Figure S1C). An average of 11.667.2% (n=42)
CD161hi cells within the CD8+ T cell population and
48.3645.96106 (n=22) CD161hiCD8+ T cells/L was observed
(Figure S1D). Reference ranges were set as the mean 6 SD to
compare cell numbers found in allo-SCT recipients with those of
healthy controls.
Reconstitution of CD161-expressing T Cells after HLA-
matched Allo-SCT
To investigate the repopulation kinetics of CD161-expressing T
cells in patients after HLA-matched allo-SCT, PBMCs isolated
from peripheral blood of 76 patients at 1, 3, 6, and 12 months
post-transplant were analyzed by flow cytometric analysis. While
the percentage of CD161+CD4+ T cells were found to be higher
compared to healthy controls, the CD161hiCD8+ T cell popula-
tion was lower (Figure 1A). Although in most patients
CD161hiCD8+ T cells were present at low frequency, in some
patients a relative high frequency of CD161hiCD8+ T cells could
be detected at one month after allo-SCT. However, the frequency
of both CD161+CD4+ as well as CD161hiCD8+ T cells diminished
CD161+CCR6+ T Cells in GVHD
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in time. However, CD161+CD4+ T cells mainly decreased from 3
months onwards, while the frequency of CD161hiCD8+ T cells
already declined after one month where after it remained relatively
stable (Figure 1A). On the other hand, the absolute number of
CD161+CD4+ and CD161hiCD8+ T cells increased in the first
months after allo-SCT, where after they stabilized but remained
below the reference ranges (Figure 1B). Meanwhile, the total
CD4+ and CD8+ T cell number expanded. From 3 months
onwards, a relative overshoot of the percentage (data not shown)
and absolute number of CD161neg/lowCD8+ T cells was observed
in a substantial proportion of the patients (Figure 1C).
Remarkably, the frequency of CD161hiCD8+ T cells was found
to be the highest in patients with a low percentage of CD3+ T cells
(data not shown) or CD8+ T cells, as observed for both absolute
levels (data not shown) as well as for percentages (Figure 1D). In
contrast, this was not observed for CD161+CD4+ T cells.
Altogether, these data show that both CD161+CD4+ T cells and
CD161hiCD8+ T cells reconstitute shortly after HLA-matched
allo-SCT. However, while CD161+CD4+ T cells were found at
higher counts compared to those of healthy controls and
reconstituted to normal levels, the percentage of CD161hiCD8+
T cells declined in time due to the expansion of the CD161neg/
lowCD8+ T cells.
CD161hiCD8+ T Cells are Relative Resistant to CsA
Treatment
Since the highest frequency and a specific decrease in the
percentage of CD161hiCD8+ T cells was observed shortly after
allo-SCT, we speculated that these cells were not affected by the
immunosuppressive drugs which is routinely supplied to our
patients in the first months after allo-SCT in order to prevent
severe GVHD. CsA can be transported out of the cell by the
ABCB1 transporter, which has been shown to be present on
CD161hi but not on CD161neg/lowCD8+ T cells [32,43]. To
determine whether the ABCB1 transporter is also present on
CD161-expressing CD4+ T cells, qPCR analysis was performed
on mRNA of sorted CD1612CD4+, CD161+CD4+, CD161neg/
lowCD8+, and CD161hiCD8+ T cells. Next to the high ABCB1
mRNA expression in CD161hiCD8+ T cells (P,0.01), this
transporter was also expressed by CD161+CD4+ T cells, though
levels were lower (Figure 2A). This difference in ABCB1 mRNA
expression levels correlated with the efflux of the fluorescent dye
Rh123 by the various subsets (Figure 2B). Especially
CD161hiCD8+ T cells displayed a more efficient Rh123-efflux
compared to their CD161neg/low counterparts. In contrast,
CD161+CD4+ T cells, expressing lower mRNA levels of ABCB1
were hardly able to efflux Rh123.
To determine whether expression of the ABCB1 multi-drug
transporter indeed mediates resistance of CD161-expressing T
cells to CsA-induced functional impairment, CFSE-labelled
PBMCs were stimulated in an MLR using irradiated allo-PBMCs
in the presence or absence of physiological levels of CsA [44].
Indeed, CsA hardly affected CD161hiCD8+ T cell proliferation,
whereas it exerted a strong dose-dependent inhibition on
proliferation of CD161neg/lowCD8+ T cells (P,0.001; Figure 2C–
D). For CD4+ T cells, no difference in CsA-mediated inhibition
was observed between CD161+ or CD1612CD4+ T cells (data not
shown). Collectively, these data demonstrate that the presence of
the ABCB1 transporter on CD161hiCD8+ T cells, but not on
CD161+CD4+ T cells, confers relative resistance from CsA
treatment.
Decreased Levels of Circulating CD161-expressing T Cells
are Associated with a Higher GVHD Incidence
To determine whether CD161-expressing T cells are associated
with the development of GVHD, statistical analysis was performed
between relative and absolute cell counts of CD161+CD4+ and
CD161hiCD8+ T cells measured in the circulation of patients at 3
months after allo-SCT and their GVHD status. Both the percentage
(39.7%, range 20.7–60.7 vs. 32.5%, range 3.25–49.44, P=0.025 )
and absolute levels (87.56106/L, range 19–218 vs. 55.36106/L,
range 4–182, P=0.009) of CD161+CD4+T cells in peripheral blood
were found to be significantly reduced in patients with acute GVHD
(Figure3A).Thisdecreasewasalsoobserved for theabsolutenumbers
of CD161hiCD8+ T cells (1.176106/L, range 0.08–5.64, vs.
0.466106/L, range 0.01–4.21, P= 0.013) (Figure 3B). In addition,
the percentage (0.62%, range 0.06–14.80, vs. 0.41%, range 0.04–
2.50,P=0.019) aswell as the absolute cell count (1.056106/L, range
0.07–5.64, vs. 0.476106/L, range 0.01–4.21, P=0.033) of circulat-
ing CD161hiCD8+ T cells were also inversely correlated with the
development of chronicGVHD(Figure 3B). Importantly, correction
for known confounders like patients’ age, gender combination, and
source of the graft had no or only minimal impact on the significant
association between decreased CD161-expressing T cell counts and
the occurrence of GVHD (Table 2). Additionally, also correction for
the relative and absolute number of total CD4+ or CD8+ T cells did
not affect on the observed correlation. These data indicate that
reduced levels of circulating CD161+CD4+ and CD161hiCD8+ T
cells correlate with an increased occurrence of GVHD.
Phenotype of CD161-expressing T Cells in Allo-SCT
Patients
To define the memory phenotype of CD161-expressing T cells
in allo-SCT patients versus healthy controls, T cell subsets were
analysed for the expression of CCR7 and CD45RA. In allo-SCT
patients, CD4+ and CD8+ T cells have an increased proportion of
effector memory cells (Tem) compared to healthy donors
(Figure 4A–B, P,0.001). Only minimal differences were found
in the differentiation status within the CD161-expressing T cell
subsets between allo-SCT patient and healthy donors. While
CD161+CD4+ T cells displayed both a central memory (Tcm) as
well as a Tem phenotype, CD161hiCD8+ T cells consisted mainly
of Tem cells. Overall, CD161-expressing T cells in allo-SCT
patients, in both the CD4+ and CD8+ T cell population, seemed to
be a bit more differentiated in their memory phenotype compared
to healthy controls.
CD161-expressing T Cells in Allo-SCT Patients Contain
High Frequency of IL17- and IFNc-producers
Next, functionality of CD161-expressing T cells was investigat-
ed by defining their cytokine production profile. Therefore,
PBMCs from both healthy controls as well as allo-SCT patients
were stimulated with PMA and ionomycin and subsequently
stained for intracellular cytokines (Figure S2). Both CD161+CD4+
as well as CD161hiCD8+ T cells showed to be dominant producers
of IL17 within their T cell compartment (Figure 5A–B, P,0.001).
Interestingly, for CD8+ T cells the percentage of IL17-secreting
cells within the CD161-expressing cells was higher in allo-SCT
patients compared to healthy controls (P,0.05). In addition, as
compared to CD1612CD4+ T cells, the frequency of IFNc-
producers was increased in CD161+CD4+ T cells of healthy
controls, but not for allo-SCT patients (Figure 5A–B, P,0.001).
Together, these data demonstrate that CD161-expressing T cells
of allo-SCT patients contain a high frequency of IFNc- and IL17-
producers.
CD161+CCR6+ T Cells in GVHD
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Figure 1. Reconstitution of CD161-expressing T cells in patients after allo-SCT. (A) Percentage of circulating CD161+ within CD4+ and
CD161hi within CD8+ T cells in patients at 1 (n= 11, 20), 3 (n= 50, 71), 6 (n= 19, 24), and 12 (n= 19, 22) months after allo-SCT. (B) Absolute levels of
circulating CD161+CD4+ and CD161hiCD8+ T cells in patients at 1 (n= 8, 20), 3 (n= 50, 71), 6 (n= 19, 24), and 12 (n= 19, 22) months after allo-SCT. (C)
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CCR6-mediated Migration of CD161-expressing T Cells to
CCL20 Present in GVHD Tissues
To explore the tissue-homing capacity of CD161-expressing T
cells in allo-SCT patients, we determined expression of the
chemokine receptor CCR6, within the corresponding memory-
phenotype. CCR6 expression was found to be elevated on both
CD161+CD4+ as well as CD161hiCD8+ T cells compared to their
CD161-negative counterparts (Figure 6A and Figure S3, P,0.05).
Next, the migration potential of CCR6+CD161-expressing T cells
towards CCL20, the sole ligand for CCR6, was determined in an
in vitro migration assay using either purified CD4+ or CD8+ T cells
isolated from healthy controls. Where CCL20 induced robust
migration of both CD161+CD4+ as well as CD161hiCD8+ T cells,
their CD161-negative counterparts were unresponsive to this
chemokine (Figure 6B; P,0.001). In addition, migration assays
were performed using purified CD3+ T cells from allo-SCT
patients. Since CD8+ T cells numbers were too low, analysis was
focused on CD4+ T cells. For these, specific migration of
CD161+CD4+ T cells towards CCL20 was observed compared
to CD1612CD4+ T cells (Figure 6C; P,0.001). These results
support the concept that CCR6 expression on CD161+CD4+ and
CD161hiCD8+ T cells facilitates preferential migration to CCL20-
expressing tissues.
To further substantiate the relevance of the CCR6-CCL20
pathway in guiding migration of CD161-expressing T cells to
GVHD-prone organs, we next determined CCL20 expression in
Absolute number of circulating CD1612CD4+ and CD161neg/lowCD8+ T cells in patients at 1 (n= 8, 20), 3 (n= 54, 69), 6 (n= 19, 24), and 12 (n= 19, 22)
months after allo-SCT. (D) Correlation between the percentage of circulating CD161+CD4+ and CD4+ T cells (n= 58), and CD161hiCD8+ T cells and
CD8+ T cells (n= 70) at 3 months after allo-SCT. Lines represent median value, grey areas represent the reference range of healthy controls (mean 6
SD). Statistical analysis was performed using a One-way ANOVA followed by a Bonferroni post-hoc test (CD4) or non-parametric One-way ANOVA
followed by a Dunns post-hoc test (CD8). Correlations were determined by calculating the Spearman correlation coefficient (R). *P,0.05, **P,0.01,
***P,0.001.
doi:10.1371/journal.pone.0050896.g001
Figure 2. CD161hiCD8+ T cells escape from functional inhibition by CsA. (A) Relative ABCB1 expression determined by qPCR on sort-purified
CD1612CD4+, CD161neg/lowCD8+ (white bars) and CD161+CD4+, CD161hiCD8+ (black bars) T cells. Expression is normalized to that of CD1612CD4+ T
cells. Data represent the mean 6 SEM of 2 independent healthy donors. (B) PBMCs were labelled with Rh123, cultured for 30 minutes, and measured
by flow cytometry for CD3, CD4, CD8, and CD161. A representative sample is shown gated on CD3+CD4+ and CD3+CD8+ T cells. (C-D) CFSE-labelled
PBMCs were stimulated in an MLR with irradiated allo-PBMCs in the presence or absence of CsA. CFSE levels were determined after 7 days of culture.
(C) Flow cytometry data of one representative experiment is shown gated on CD3+CD8+ T cells. Numbers represent percentages of proliferation per
subset. (D) Relative proliferation is depicted as the percentage proliferating CD161neg/lowT cells (white bars) and CD161hiCD8+ T cells (black bars)
compared to the condition without CsA, as mean+SD (n= 3). One representative experiment out of 3 independent healthy donors is shown.
Statistical analysis was performed using One way ANOVA followed by a Bonferroni post-hoc test. *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0050896.g002
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situ in skin biopsies obtained from allo-SCT recipients who
developed acute or chronic GVHD (Figure 7A, Figure S4).
CCL20 expression could be clearly visualized in the epidermis of
the skin. Moreover, CCL20 was also expressed on single cells
present in the dermis in close proximity to the epidermal-dermal
junction that is typically targeted by infiltrating T cells.
Figure 3. Circulating CD161+CD4+ and CD161hiCD8+ T cells are decreased in allo-SCT patients who develop GVHD. (A) Comparison of
percentage and absolute levels of circulating CD161+CD4+ T cells in patients 3 months after allo-SCT and the occurrence of acute GVHD (Percentage,
No n= 28, Yes n= 22; Absolute, No n= 28, Yes n= 22) and chronic GVHD (Percentage, No n= 35, Yes n= 15; Absolute, No n= 35, Yes n= 15). (B)
Comparison of percentage and absolute numbers of circulating CD161hiCD8+ T cells in patients 3 months after allo-SCT and the occurrence of acute
GVHD (Percentage, No n= 34, Yes n= 34; Absolute, No n= 34, Yes n= 32) and chronic GVHD (Percentage, No n= 46, Yes n= 22; Absolute, No n= 46,
Yes n= 20). Lines represent mean (CD4) or median (CD8) values. Statistical analysis was performed using univariate logistic regression analysis.
*P,0.05, **P,0.01.
doi:10.1371/journal.pone.0050896.g003
Table 2. Multi-variable analysis of GVHD.
CD161+CD4+ T cells CD161hiCD8+ T cells
% OR (95% CI) 106/L OR (95% CI) % OR (95% CI) 106/L OR (95% CI)
Acute GVHD
Without correction P = 0.025 0.928 (0.870–0.991) P = 0.009 0.330 (0.143–0.761) P= 0.811 0.958 (0.675–1.359) P= 0.013 0.570 (0.366–0.888)
Corrected for
2 Age of the patient P = 0.024 0.926 (0.866–0.990) P = 0.009 0.328 (0.142–0.757) P= 0.678 0.927 (0.647–1.327) P= 0.014 0.567 (0.362–0.890)
2 Gender combination P = 0.088 0.943 (0.881–1.009) P = 0.014 0.344 (0.146–0.808) P= 0.798 0.950 (0.641–1.409) P= 0.048 0.631 (0.400–0.997)
2 Source graft P = 0.027 0.929 (0.870–0.991) P = 0.009 0.325 (0.140–0.754) P= 0.819 0.960 (0.676–1.363) P= 0.011 0.560 (0.359–0.873)
2 T cell subset (%) P = 0.022 0.925 (0.865–0.989) P = 0.010 0.336 (0.147–0.771) P= 0.371 0.827 (0.546–1.254) P= 0.021 0.567 (0.350–0.918)
2 T cell subset (106/L) P = 0.009 0.909 (0.846–0.976) P = 0.011 0.098 (0.017–0.583) P= 0.221 0.763 (0.495–1.177) P= 0.025 0.577 (0.357–0.933)
Chronic GVHD
Without correction P = 0.140 0.956 (0.900–1.015) P = 0.700 0.868 (0.427–1.765) P= 0.019 0.588 (0.377–0.918) P= 0.033 0.634 (0.418–0.963)
Corrected for
2 Age of the patient P = 0.147 0.956 (0.899–1.016) P = 0.678 0.859 (0.420–1.759) P= 0.012 0.542 (0.336–0.876) P= 0.035 0.635 (0.416–0.969)
2 Gender combination P = 0.340 0.970 (0.910–1.033) P = 0.838 0.929 (0.446–1.926) P= 0.012 0.473 (0.264–0.847) P= 0.030 0.594 (0.372–0.951)
2 Source graft P = 0.242 0.961 (0.899–1.027) P = 0.612 0.816 (0.373–1.788) P= 0.017 0.578 (0.369–0.906) P= 0.064 0.666 (0.432–1.025)
2 T cell subset (%) P = 0.128 0.953 (0.896–1.014) P = 0.706 0.872 (0.427–1.779) P= 0.006 0.473 (0.278–0.807) P= 0.028 0.588 (0.366–0.943)
2 T cell subset (106/L) P = 0.251 0.964 (0.905–1.026) P = 0.082 0.291 (0.073–1.169) P= 0.006 0.428 (0.235–0.781) P= 0.014 0.544 (0.355–0.884)
Abbreviations: OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0050896.t002
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Finally, to confirm homing of CD161+CCR6+ co-expressing T
cells to GVHD tissues, skin biopsies of GVHD patients were
examined for the presence of CCR6+ T cells. Infiltrated T cells
were clearly visible in the skin derived from both acute as well as
chronic GVHD patients, of which several cells displayed
expression of CCR6 (Figure 7B). Among these cells, both
CD3+CD4+ as well as CD3+CD42 T cells were detected. Also
in GVHD-affected gut tissue, expression of CCL20 and
CCR6+CD3+ T cells could be detected (Figure S5). These data
strengthen our hypothesis that the observed decrease of CD161-
expressing T cells from the circulation in GVHD patients is the
result of their homing to CCL20-expressing GVHD tissues.
Discussion
Th17 cells have been linked to the pathophysiology of GVHD,
however data remains limited and contradictory [8–15]. Recently,
correlations have been made between Th17 and Tc17 cells and
their involvement in GVHD using the well-established CD161
lineage-identifier for IL17-producing CD4+ and CD8+ T cells
subsets [16,18,19,26]. The involvement of CD161-expressing T
cells is further supported by their responsiveness to IL1ß [26], a
key cytokine involved in GVHD [1,45]. In this study, we
investigated the repopulation kinetics of both CD4+ and CD8+
CD161-expressing T cells in allo-SCT patients, and their potential
role in the development of GVHD. Remarkably, the relative
proportion of CD161+ cells within the CD4+ T cells compartment
was higher in allo-SCT patients compared to healthy controls.
Furthermore, while CD161+CD4+ T cells reconstituted allo-SCT
patients in a relatively balanced way, we found that the
CD161hiCD8+ T cell frequency decreases within the first 3
months after allo-SCT, where after it remained stable at a low
level. Interestingly, this relative decrease occurred during tapering
of CsA, which is normally started two months after allo-SCT when
GVHD is absent. During these first months after allo-SCT,
CD161hiCD8+ T cells, expressing the ABCB1 transporter, have a
proliferative advantage over CD161neg/lowCD8+ T cells as
evidenced by their clear in vitro resistance to the CsA-mediated
Figure 4. Memory phenotype of CD161-expressing T cells. (A) Memory phenotype of total CD4+ T cells (left panel) and CD161+CD4+ T cells
(right panel) in healthy controls (#, n= 18) and patients 3 months after allo-SCT (N, n= 55). (B) Memory phenotype of total CD8+ T cells (left panel)
and CD161hiCD8+ T cells (right panel) in healthy controls (#, n= 18) and patients 3 months after allo-SCT (N, n= 55 and n= 52 respectively). Tn, naı¨ve
(CCR7+CD45RA+); Tcm, central memory (CCR7+CD45RA-); Tem, effector memory (CCR72CD45RA-); TemRA, CD45RA+ effector memory
(CCR72CD45RA+). Statistical analysis was performed using One-way ANOVA followed by a Bonferroni post-hoc test. *P,0.05, ***P,0.001.
doi:10.1371/journal.pone.0050896.g004
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inhibition of T cell proliferation. During tapering of CsA, this
advantage gradually disappeared, which could explain the rise of
CD161neg/lowCD8+ T cells and a relative decline of CD161hiCD8+
T cells. Furthermore, it has been described that CD161hiCD8+ T
cells have a lower proliferation capacity compared to CD161neg/
lowCD8+ T cells [31], which might result in a more robust
expansion of CD161neg/lowCD8+ T cells at later time points after
allo-SCT. Additionally, cell death as well as the administration of
various drugs, like steroids for the treatment of GVHD, will also
influence the repopulation kinetics shortly after allo-SCT.
However, it is likely that the ABCB1-dependent CsA-efflux
favours early repopulation of CD161hiCD8+ T cells following
allo-SCT.
In this current study, we are the first to show a correlation
between reduced levels of circulating CD161+CD4+ and
CD161hiCD8+ T cells and the occurrence of GVHD. Interesting-
ly, a significant decreased frequency was observed in PB samples 3
months after allo-SCT from patients who had acute GVHD or
who developed chronic GVHD later on. This information is of
considerable significance as GVHD, of which the pathogenesis is
still not fully understood, is the most profound adverse complica-
tion after allo-SCT [1,46].
Although the number of patients analysed in this study did not
allow statistical analysis for multiple confounding parameters at
once, we found that the association between decreased CD161-
expressing T cells and GVHD remained independent from the
total CD4+ or CD8+ T cell number and known confounders such
Figure 5. IL17 and IFNc production of CD161-expressing T cells after allo-SCT. (A) Representative IL17 and IFNc production by intracellular
cytokine staining from a healthy control and allo-SCT patient. Numbers plot indicate the percentage of cells in each quadrant. (B) Comparison of IL17
(left panels) and IFNc (right panels) production, measured by intracellular cytokine staining, between CD1612 and CD161+CD4+ T cells, and CD161neg/
low and CD161hiCD8+ T cells in healthy controls (#) and patients 1–3 months after allo-SCT (N). Data is shown as the percentage of positive cells, lines
represent mean value. Statistical analysis was performed using One-way ANOVA followed by a Bonferroni post-hoc test, or a one-tailed paired
student t-test. *P,0.05, ***P,0.001.
doi:10.1371/journal.pone.0050896.g005
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Figure 6. Preferential migration of CD161-expressing T cells to CCL20. (A) Comparison of CCR6 expression between CD1612 and
CD161+CD4+ memory T cells, and CD161neg/low and CD161hiCD8+ Tem cells of healthy donors (’) and patients 3 months after allo-SCT (N). The
frequency of CD161+CD4+ T cells in the measured samples was 34.6–55.7% in allo-SCT patients (n= 10) and 36.6–46.4% in healthy controls (n= 3), and
the frequency of CD161hiCD8+ T cells was 0.05–23.8% in allo-SCT patients (n= 8) and 11.5–42.4% in healthy controls (n= 3). Data is shown as mean
fluorescent intensity (MFI). Lines represent mean value. (B) Migration of CD4+ and CD8+ T cell subsets to CCL20. CD4+ or CD8+ T cells were applied to
the upper chamber and migrated to the lower chamber containing medium with or without CCL20. Migrated cells were analysed by flow cytometry.
Migration is shown relative to input (mean 6 SD) for CD1612CD4+ and CD161neg/lowCD8+ T cells (dashed line), and CD161+CD4+ and CD161hiCD8+ T
cells (solid line) (n= 3). One representative experiment out of 2 (CD4) or 3 (CD8) independent healthy donors is shown. (C) Migration of CD4+ T cell
subsets to CCL20. CD3+ T cells were applied to the upper chamber and migrated to the lower chamber containing medium with or without CCL20.
Migrated cells were analysed by flow cytometry. Migration is shown relative to input (mean 6 SD) for CD1612CD4+ (dashed line), and CD161+CD4+
(solid line) (n = 3). Two independent patients 3 months after allo-ST are shown. Statistical analysis was performed using Two-way ANOVA followed by
a Bonferroni post-hoc test. *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0050896.g006
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as age, gender combination and graft source. Due to insufficient
data, we were unable to take CsA blood levels along as a
confounder in this study. However, if CsA levels in the patients’
blood would have interfered with the correlation of CD161-
expressing T cells and GVHD, it is expected that higher CsA levels
in GVHD patients would result in higher levels of CD161-
expressing T cells due to their CsA resistance. Therefore, the
found correlation between decreased levels of CD161-expressing
T cells and GVHD would even be an underestimation.
Based on the found association, we speculated that the decrease
in circulating CD161-expressing T cells results due to specific
recruitment into GVHD-affected tissues. Prevalent expression of
CCR6, as well as the migration potential of both CD161+CD4+
cells and CD161hiCD8+ T cells to inflamed tissues, and their
involvement in several inflammatory disorders have been
described previously [25,28,30,35]. Furthermore, our observations
are in agreement with the recent study of Bossard et al. [16], who
observed increased numbers of CD161+, RORct+ and CCR6+
cells in GVHD-affected intestinal mucosa. Therefore, our findings
support the pathogenic role of CD161+CCR6+ co-expressing T
cells, preferentially containing Th17 and Tc17 cells, in GVHD
developing after allo-SCT.
Whether CD161-expressing T cells are directly involved in the
onset and/or aggravation of GVHD remains to be proven.
However, IL1a as well as IL1ß, which are part of the cytokine
storm created after conditioning of the patient [5,45], could result
in elevated CCL20 production in GVHD-prone tissues. This
possibility was shown by culturing endometriotic stromal cells in
the presence of IL1ß, which increased their CCL20 secretion
considerably [35]. Also damage to the skin, as well as culture of
keratinocytes with IL1a increases CCL20 secretion [36]. Addi-
tionally, in agreement with other studies we have found that
CD161+CD4+ and CD161hiCD8+ T secrete IFNc and IL17
[18,22,26,27,30]. Interestingly, the IL17 production of CD161-
expressing T cells is further increased after culturing these cells
with IL1ß alone or in conjunction with IL23 [18,26]. Migration of
CCR6+CD161-expressing T cells to the GVHD-prone tissues
could thereby result in IL17 production, priming the GVHD
response, further enhancing CCL20 production, and recruiting
other effector cells. Our data indicate that the decrease in
percentage of CD161hiCD8+ T cells, already at 3 months after
allo-SCT, could be an early sign of the clinical onset of chronic
GVHD later on. All together, these data suggest that CD161-
expressing CD4+ and CD8+ T cells with IL17 and/or IFNc
secreting properties, are involved in the onset of GVHD.
In conclusion, here we show that following allo-SCT, patients
are readily reconstituted with CD161-expressing T cells. Interest-
ingly, the resistance of CD161hiCD8+ T cells for CsA-mediated
inhibition of proliferation might explain their observed repopula-
tion kinetics. Most importantly, we observed that a decrease of
both circulating CD161+CD4+ as well as CD161hiCD8+ T cells
coincided with the occurrence of both acute and chronic GVHD.
In fact, we demonstrate that the reduced number of CD161-
expressing T cells could be seen as an independent predictor of
GVHD, and that CCR6+CD161-expressing T cells may be
involved in the immune pathology of GVHD following their
CCL20-dependent recruitment into affected tissues.
Supporting Information
Figure S1 CD161+CD4+ and CD161hiCD8+ T cells in
healthy adults. (A) Flow cytometry data of a representative
healthy control gated on circulating CD3+ cells. CD1612CD4+
and CD161+CD4+ T cell populations are depicted in the gates. (B)
Percentage and absolute numbers of circulating CD161+ within
CD4+ T cells in healthy adults (n=16). (C) Flow cytometry data of
a representative healthy control gated on CD3+ cells. CD161neg/
lowCD8+ and CD161hiCD8+ T cell populations are depicted in the
gates. (D) Percentage and absolute levels of circulating CD161hi
within CD8+ T cells in healthy adults (n=42, n=22). Lines
represent the mean value.
(TIF)
Figure S2 IL17 and IFNc production determined by
intracellular staining. Gating strategy of intracellular cytokine
staining for IL17 and IFNc 4 h after stimulation with PMA and
ionomycin.
(TIF)
Figure S3 CCR6 is higher expressed on CD161-express-
ing T cells. Representative flow data of CCR6 expression on
CD161-expressing CD4+ or CD8+ T cells in a patient after allo-
SCT. Numbers represent the mean fluorescent intensity of the
subset.
(TIF)
Figure S4 CCL20 expression in GVHD affected skin
tissue. (A) Negative (without CCL20-specific antibody) and
positive (B) control staining for CCL20 in foreskin. (C) CCL20
staining in skin biopsies of two additional patients, conditioned
with Cyclo-ATG-Bus (cyclophosphamide-antithymocyte globulin-
busilvex) and Flu-Mel-Alem (fludarabine-melphalan-alemtuzu-
mab), who were diagnosed with acute GVHD at respectively 41
(UPN 1001) and 18 (UPN 10019) days after allo-SCT. Squares
indicate examples of single cells in the epidermis which are
situated in close proximity to the epidermal-dermal junction.
Images were captured at 400X.
(TIF)
Figure S5 CCL20 expression and CCR6+ T cells in
GVHD affected gut tissue. (A) CCL20 (brown) and (B) CD3
(red), CD4 (blue), and CCR6 (green) triple staining in a gut biopsy
of a patient after allo-SCT diagnosed with acute GVHD at 34 day
after allo-SCT (UPN 902). White arrows and squares indicate
examples of CD3+CD4+CCR6+ cells, yellow arrows and squares
indicate examples of CD3+CD42CCR6+ cells. Single stainings of
the cells in squares are depicted under the image. Images were
captured at 400X.
(TIF)
Figure 7. CCL20 is expressed in GVHD tissues and selectively attracts CCR6+ T cells. (A) CCL20 staining in skin biopsies of patients
diagnosed with acute GVHD at respectively 49 (UPN 833) and 30 days (UPN 877), or chronic GVHD 127 days (UPN 722) and 321 days (UPN 741) days
after allo-SCT. Squares indicate examples of single cells in the dermis in close proximity to the epidermal-dermal junction (acute GVHD) or in the
epidermis which are situated in close proximity to or at the epidermal-dermal junction (chronic GVHD). Images were captured at 400X. (B) CD3 (red),
CD4 (blue), and CCR6 (green) triple staining in skin biopsies of patients diagnosed with acute GVHD at respectively 49 (UPN 833) and 30 days (UPN
877), or chronic GVHD 127 days (UPN 722) and 321 days (UPN 741) days after allo-SCT. White arrows and squares indicate examples of
CD3+CD4+CCR6+ cells, yellow arrows and squares indicate examples of CD3+CD42CCR6+ cells. Single stainings of the cells in squares are depicted
under the image. Images were captured at 400X.
doi:10.1371/journal.pone.0050896.g007
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